FDA

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

“Receiving Fast Track designation from the FDA reinforces the potential [...]

By |2025-01-08T15:55:49+00:00January 8, 2025|3rd Party Medical Device Industry News|Comments Off on Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

Christopher M. Owens, President and Chief Executive Officer of R3 [...]

By |2024-11-04T14:33:59+00:00November 4, 2024|3rd Party Medical Device Industry News|Comments Off on FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
Go to Top